Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide

Blood

Volumn 91, Issue 11, 1998, Pages 4197-4205

  Herbert, J M ^a   Herault J P ^b   Bernat, A ^b   Van Amsterdam, R G M ^b   Lormeau, J C ^b   Petitou, M ^b   Van Boeckel, C ^b   Hoffmann, P ^b   Meuleman, D G ^b  

^a SANOFI   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOLYTIC AGENT; HEPARIN; IDRAPARINUX; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; EAR INJURY; FIBRINOLYTIC THERAPY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; THROMBOSIS;

EID: 2642617786     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.11.4197.411k09_4197_4205     Document Type: Article

References (27)

1. Verstraete M: Pharmacotherapeutic aspects of unfractionnated and low molecular weight heparins. Drugs 40:498, 1990
2. Verstraete M, Zoldhelyi P: Novel antithrombotic drugs in development. Drugs 49:856, 1995
3. CAA Van Boeckel, Petitou M: The unique antithrombin binding domain of heparin: A lead to new synthetic antithrombotics. Angew Chem Ind 32:1671, 1993
4. Béguin S, Choay J, Hemker HC: The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 61:397, 1989
5. Vogel GM, Meuleman DG, Bourgondiën FG, Hobbelen M: Comparison of two experimental thrombosis models in rats: Effect of four glycosaminoglycans. Thromb Res 54:399, 1989
6. Hobbelen PMJ, Van Dinther TG, Vogel GMT, Van Boeckel CAA, Moelker HCT, Meuleman DG: Pharmacological profile of the chemically synthetized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost 63:265, 1990
7. Walenga JM, Fareed J, Petitou M, Samama M, Lormeau JC, Choay J: Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model. Thromb Res 43:243, 1986
8. Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J: Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 46:187, 1987
9. Cadroy Y, Hansson SR, Harker LA: Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Thromb Haemost 70:631, 1993
10. Boneu B, Necciari J, Cariou R, Sié P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T, Magnani H: Pharmacokinetics and tolerance of the natural pentasaccharide (SR 90107/ORG 31540) with high affinity to antithrombin III in man. Thromb Haemost 74:1468, 1995
11. Herbert JM, Hérault JP, Bernât A, Van Amsterdam RGM, Vogel GMT, Lormeau JC, Petitou M, Meuleman DG: Biochemical and pharmacological properties of Sanorg 32701 - Comparison with the "syntheric pentasaccharide" (SR 90107/ORG 31540) and standard heparin. Circ Res 79:590, 1996
12. Van Amsterdan RGM, Vogel GMT, Visser A, Kop WJ, Buiting MT, Meuleman DG: Synthetic analogs of the antithrombin III-binding pentasaccharide sequence of heparin - Prediction of the in vivo residence times. Arterioscler Thromb Vasc Biol 15:495, 1995
13. Teien AN, Lie M: Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb Res 13:285, 1978
14. Hemker HC, Willems GM, Béguin S: A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 56:9, 1986
15. Lormeau JC, Herault JP: Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide. Thromb Haemost 69:152, 1993
16. Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J: Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. Biochemistry 26:6454, 1987
17. Buchanan MR, Boneu B, Ofosu FA, Hirsh J: The relative importance of thrombin and factor Xa to the antithrombotic effect of heparin. Blood 65:198, 1985
18. Boneu B, Buchanan MR, Cade JF, Van Ryn TM, Fernandez FF, Ofosu FA, Hirsh J: Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb Res 40:81, 1985
19. Collen D, Stassen JM, Verstraete M: Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest 71:368, 1983
20. Hoffmann P, Bernat A, Savi P, Herbert JM: Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: Comparison with clopidogrel and aspirin. J Cardiovasc Pharmacol 30:360, 1997
21. Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J: Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. J Biol Chem 267:12528, 1992
22. Choay J, Petitou M, Lormeau JC, Sinay P, Casu BJ, Gatti G: Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 116:492, 1983
23. Masys DR, Bajaj SP, Rapaport SI: Activation of human factor VII by activated factors IX and X. Blood 60:1143, 1982
24. Lormeau JC, Herault JP, Herbert JM: Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb Haemost 76:5, 1996
25. Carrie D, Caranobe C, Saivin S, Houin G, Petitou M, Lormeau JC, Van Boeckel C, Meuleman D, Boneu B: Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: Comparison with CY 216. Blood 84:2571, 1994
26. Hérault JP, Donat F, Bàrzu T, Crépon B, Bernat A, Lormeau JC, Herbert JM: Pharmacokinetic study of three synthetic ATIII-binding pentasaccharides in various animal species - Extrapolation to humans. Blood Coagul Fibrinol 8:161, 1997
27. Eisenberg PR, Jeffrey ES, Abendschein DR, Miletich JP: Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 91:1877, 1993